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THE FIRST report on FK506 (FK) was 
made by Ochiai et all in Helsinki in 
1986. Since then, our efforts have been 
designed to clarify the efficiency and the 
toxicity of this agent. In vitro systems and 
experimental organ transplantation models 
have been used for testing. Several reports of 
this work have been published.2- lo We describe 
here the cumulative information and further 
follow-up of the whole organ transplantation 
studies. 
MATERIALS AND METHODS 
Animals and Operative Procedures 
FK was tested in three different models of experimen-
tal organ transplantation: heterotopic heart transplanta-
tion in the rat (HTX). 2.S.' kidney transplantation in the 
dog (KTX).J·6 and orthotopic liver transplantation in the 
dog (OLTX).J·7 
Animal species and operative procedures were 
described in the previous reports. In brief. HTX2.s .• was 
performed intra-abdominally from ACI rats (RT 1&) to 
Lewis rats (RT 11). Brown Norway rats (RT I") were 
used as donors where third-party grafts were involved. 
KTX was performed using mongrel dogs as donors aRd 
beagle dogs as recipients. using conventional intra-
abdominal techniquesJ·6; native kidneys were removed at 
the end of operation. In dogs under a pump driven 
veno-venous bypass. OL TX was carried out from beagle 
donors to beagle recipients (B/B) or from mongrel donors 
to beagle recipients (M/B).J·7 
Nephrotoxicity of FK was tested in rats whose test 
kidneys were submitted to one-hour ischemia by cross 
clamping. followed by contralateral nephrectomy. 
Drug Administration 
FK was supplied by the Fujisawa Pharmaceutical 
Company. Ltd. Osaka. Japan. It was dissolved in saline 
for intramuscular use or placed in commercial capsules 
for oral use. Cyclosporine (CyA) in the commercial oil 
carrier that is used clinically was given orally by syringe. 
Prednisone (Pred) for oral use in dogs was given in 5-mg 
tablets. To prevent vomiting in the dog caused by FK or 
other postoperative factors. 2 mg of atropine sulphate was 
given intramuscularly twice a day for the first postopera-
tive week and once a day for the second postoperative 
week. 
Dose Effectiveness Studies 
The effectiveness of FK in HTX was reported previ-
ously by Lee et al2 and Murase et al.s Seven different 
intramuscular doses of FK from 0.02 mg/kg/d to 1.28 
mg/kg/d were tested. FK was given for 2 weeks starting 
just after recovery from anesthesia. 
The effect of oral doses on canine KTX was tested at 
0.5. 1.0. 1.5. and 2.0 mg/kg/d. FK was started on the 
morning after the operation and continued for 3 months. 
The initial doses were reduced to 75% after 2 months. 
The effect of FK alone was further evaluated in OL TX. 
starting with 1.0 mg/kg/d of oral FK. The dose was 
adjusted to 75% of the initial dose after 1 month. 
Drug Combination Studies 
In HTX. minimally effective doses of intramuscular 
FK (0.02 mg/kg/d and 0.04 mg/kg/d) and cyclosporine 
(CyA) (2.5 mg/kg/d) were used together. In canine 
KTX. oral FK (0.5 mg/kg/d). CyA (5 mg/kg/d) and 
Pred (5 mg/kg/d) were used in five combination groups 
(see RESULTS for groups). 
Delayed Treatment 
FK was given intramuscularly for three days starting at 
different times postoperatively. Rats with HTX were 
treated with an intramuscular dose of 1.28 mg/kg/d and 
dogs with KTX were treated with an intramuscular dose 
of 1.0 mg/kg/d. 
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Toxicity Studies 
Nontransplanted Lewis rats and beagle dogs were 
subjected to toxicity studies. FK was given orally to the 
rat for 5 weeks at doses of 0.5. 1.0. 2.0. and 4.0 mg/kg/d. 
Dogs were treated for 4 weeks with oral FK at doses of 
1.0. 2.0. and 4.0 mg/kg/d. Functional and histopatho-
logic changes in rats were reported earlier by Nalesnik et 
al.lO 
Nephrotoxicity of FK and CyA was compared in rats 
by using a renal ischemia model in which the right renal 
pedicle was crossclamped for one hour. followed by 
contralateral nephrectomy. Animals were orally treated 
for ten days starting two days prior to the ischemia. Doses 
of FK tested were 1.0. 2.0. and 4.0 mg/kg/d. The CyA 
dose was 25 mg/kg/d. 
RESULTS 
Dose Effectiveness Studies 
HTX Grafts of untreated rats were 
rejected in six days. Graft survival was signifi-
cantly increased by FK administration at all 
doses tested intramuscularly. The median sur-
vival was eight days with 0.02 mg/kg/d. 10.5 
days with 0.04 mg/kg/d, 32.0 days with 0.08 
mg/kg/d, 32.0 days with 0.16 mg/kg/d. 38.0 
days with 0.32 mg/kg/d, 39.0 days with 0.64 
mg/kg/d, and 87.0 days with 1.28 mg/kg/d. 
KTX Survival of animals in each group is 
shown in Fig 1. The best results were with 1.5 
mg/kg/d of FK orally. 
OLTX The survival of ten dogs is shown 
in Fig 2. Two dogs died of intussusception and 
biliary peritonitis at day 6 and at day 10, 
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respectively. They had no rejection. The other 
eight dogs treated with oral doses of I mg/ 
kg/d lived more than I month with good graft 
function. However, after reducing the FK 
dose to 0.75 mg/kg/d at the 31st postopera-
tive day, rejection occurred in four dogs. 
Three were M/B combination and the other 
was B/B combination. Four dogs lived for 
more than 3 months. Three were B/B and one 
was M/B. After discontinuation of treatment 
at 90 days, one dog died at day 98 and another 
died at day 147. The other two are still alive 
after 150 days and 162 days. Both were B/B. 
In comparison to a previous study of CyA in 
our laboratory, II the graft function during the 
first postoperative month was better in ani-
mals treated with FK.7 Four of nine animals 
had rejection within 1 month when treated 
with 20 mg/kg/d of CyA, while no rejection 
occurred during the same period in animals 
treated with I mg/kg FK. 
Drug Combinations 
HTX: Small doses of FK alone caused a 
barely detectable increase in graft survivaV to 
8.0 days with 0.02 mg/kg/d and to 10.5 days 
with 0.04 mg/kg/d. With CyA alone, survival 
was 10.0 days with 2.5 mg/kg/d. When both 
agents were used together, the graft survival 
was prolonged almost three times. 
KTX: The graft survival of KTX using 
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Fig 1. Survival after KTX 
of dogs treated with different 
doses of FK. 
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combination therapy is shown in Fig 3. Only 
one dog survived for more than 3 months when 
5 mgjkgjd CyA and 5 mg Pred were given 
together; the mean survival was 31.6 days (12 
to > 115 days). In contrast, combina tion ther-
apy with 0.5 mgjkg/d FK, 5 mg/kgjd CyA, 
and 5 mg Pred allowed five animals (80%) to 
live for more than 3 months, for a mean 
survival of 93.0 days (23 to 120 days). When 
the doses of the three drugs were cut in half, 
there was no thereapeutic effect. Using 0.5 
mgjkgjd FK with 5 mgjkgjd CyA, three 
dogs (50%) are still alive after 3 months. The 
mean survival was 51.8 days (12 to >87 
days). 
Delayed Treatment 
HTX. The administration of FK for three 
days only always prolonged graft survival 
compared to a mean survival of six days in 
untreated controls. The median graft survival 
was 35 days in rats treated on days 0,1, and 2. 
It was 89 days in rats treated from days 4 to 6. 
A heart grafted to the same recipient from 
another ACI rat 2 weeks after the first graft-
ing was accepted without further therapi and 
both grafts were finally rejected at approxi-
mately 2 to 3 months. If the second grafts 
were from BN rats, these were always rejected 
at similar intervals as the control indicating 
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* Data from the prevIous study 
(Todo. S. et (II, Transplantation, 1986) 
that temporary donor-specific unresponsive-
ness in recipient rats had been achieved.5 
KTX. Mean survival was 13.0 days in 
untreated animals. The mean survival was 
prolonged to 26.3 days (21 to >55 days) in 
dogs given FK at postoperative days 1, 2, and 
3; and to 27.8 days (8 to >55 days) in dogs 
given FK on days 4, 5, and 6 (Fig 4). Even 
when FK was given at seven, eight, and nine 
days after transplantation. three of seven ani-
mals are still alive for more than 48 days. 
Toxicity in Rats 
No significant histopathologic abnormali-
ties suggesting drug toxicity were detected in 
rats. IO There were dose-dependent changes in 
body weight, medullary atrophy of the thy-
mus, perivascular eosinophilia in the lung, and 
single cell necrosis of pancreatic acinar cells. 
Blood glucose was elevated in these animals. 
There was no clinicopathologic evidence of 
vasculitis in the raL IO 
Administration of FK and CyA to rats 
subjected to renal ischemia showed that FK 
had less nephrotoxicity than CyA. The peak 
creatinine at the first postoperative day was 
2.18 ± 0.70 (SD) mgjdL in untreated group; 
2.90 ± 0.44 in rats with 1 mgjkgjd FK; 3.00 
± 0.69 in rats with 2 mgjkgjd FK; 3.22 ± 
0.70 in rats with 4 mgjkgjd FK, and 4.92 ± 
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Fig 3. Survival after KTX 
of dog. treated with drug com-
bination •. 
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0.57 in rats with 25 mg/kg/d of CyA. The 
rises were most significant in CyA treated 
rats. 
Toxicity in Dogs 
Dogs receiving oral doses of FK greater 
than 0.5 mg/kg/d showed remarkable ema-
ciation and vomiting. In addition, 11 intussus-
ceptions occurred among 96 operated animals, 
of which four were KTX dogs treated with the 
highest dose of FK. Vasculitis was the most 
important finding in dogs. Animals given 4 
mg/kg/d of FK for toxicology studies showed 
medial necrosis of small arteries as early as 2 
weeks after beginning treatment. Although 
slight but definite vascular changes were 
detected even in untreated KTX dogs, these 
findings were significantly increased by the 
treatment with FK. Single necrosis of pan-
creatic acinar cells was often seen. There was 
no liver dysfunction in KTX animals, nor was 
there Cr elevation in OLTX dogs. Complete 
histologic analyses of FK toxicity in rats and 
dogs is under investigation. 
DISCUSSION 
In confirmation of the previous observa-
tions by Ochiari et al,1 and by US,2.3.5-7 the 
potency of FK was evident in this study with 
longer follow-up. Treatment with FK alone 
allowed substantial prolongation of graft sur-
vival. The optimal therapeutic dose of this 
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Fig 4. Change. in .erum creatinine after KTX in 
dogs treated with only three daily do.e. of FK. 
FK506 IN EXPERIMENTAL ORGAN TRANSPLANTATION 
drug, when given orally to KTX dogs, was 
between 1.0 mg/kg/d and 1.5 mg/kg/d. In 
OL TX animals, the reduction of dose from 1.0 
mg/kg/d to 0.75 mg/kg/d led to the loss of 
half of the animals from delayed rejection. 
Drug blood levels will be necessary to refine 
the therapeutic dose of FK. 
Combination therapy with low doses of FK, . 
CyA, and steroids was remarkably effective in 
all KTX groups. The finding was consistent 
with observations in the HTX model, indicat-
ing synergism of FK with CyA and steroids.s 
Zeevi et al9 have reported a more than addi-
tive effect of FK and CyA in in vitro studies. 
Another interesting result was the effec-
tiveness of three postoperative doses of FK 
after KTX, even though the initiation of treat-
ment was delayed for as long as seven days, 
when grafts were anticipated to have severe 
rejection. Delayed FK even at this late time 
allowed prolonged graft survival in half of the 
animals. This ability of FK suggests the possi-
bility of minimizing the use of immunosup-
pressive drugs immediately after the opera-
tion and opens the possibility of using FK to 
rescue grafts from established rejection. 
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The toxIcity of FK may be a species-
specific phenomenon. Significant histopatho-
logic changes seen in dogs, did not develop in 
rats except for minor changes in the pancreas. 
Single acinar cell necrosis was found in the 
pancreas of both rats and dogs, although it 
was mild in rats. 
Nephrotoxicity of FK was less than that of 
CyA as revealed in an ischemia model. One of 
the most important side-effects of FK in the 
dog was the medial necrosis of small arteries, 
which was severe enough to lead to focal 
necrosis or infarction of the heart. This was 
never seen in rats receiving much higher doses 
of FK. Toxicology in subhuman primates is 
now under investigation. 
SUMMARY 
FK506 is the most potent immunosuppres-
sive agent known. Its toxicity is substantial in 
dogs, minor in rats, and unknown in subhu-
man primates. In small doses that are non-
toxic even in dogs, it can be used in synergistic 
combination with cyclosporine, steroids, and 
presumably other drugs. 
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